Clinical Trials
190 trialsNCT05712356 2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2 Terminated
NCT06704724 2026-05-22
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Phase 1 Terminated
NCT05567835 2026-04-09
TOGAR
Baylor College of Medicine
Phase 2 Terminated
NCT02997332 2026-03-23
MEDINDUCTION
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Terminated
NCT02724202 2026-02-06
Curcumin in Combination With 5FU for Colon Cancer
Baylor Research Institute
Phase EARLY_PHASE1 Terminated
NCT06739252 2026-01-28
Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA
Peking University
Phase 2 Terminated
NCT06332079 2026-01-05
HAITI
Gruppo Oncologico del Nord-Ovest
Phase 2 Terminated
NCT05171166 2025-12-18
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
Peking University
Phase 2/3 Terminated
NCT06509906 2025-12-18
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
EMD Serono
Phase 1 Terminated
NCT02688803 2025-12-04
OTT15-04
Ottawa Hospital Research Institute
Phase 4 Terminated
NCT04854499 2025-11-19
ELEVATE HNSCC
Gilead Sciences
Phase 2 Terminated
NCT05417386 2025-11-18
FOLFIRINOX + NIS793 in Pancreatic Cancer
Massachusetts General Hospital
Phase 1 Terminated
NCT04363801 2025-10-09
DisTinGuish
Leap Therapeutics, Inc.
Phase 2 Terminated
NCT05678257 2025-09-12
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NuCana plc
Phase 2 Terminated
NCT00766142 2025-08-29
COCHISE
Institut Bergonié
Phase 2 Terminated
NCT04141995 2025-08-07
FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
University of Nebraska
Phase 2 Terminated
NCT05330429 2025-07-01
ELEVATE CRC
Gilead Sciences
Phase 2 Terminated
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02420509 2025-06-04
Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis
University of California, San Diego
Terminated
NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
NCT03387592 2025-03-10
SENECA
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Terminated
NCT03822936 2025-02-13
PIOPPO
CNAO National Center of Oncological Hadrontherapy
Phase 2 Terminated
NCT03117972 2025-02-05
CLavSyn
Centre Hospitalier Universitaire de Besancon
Phase 2 Terminated
NCT03736720 2025-01-30
Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
Roswell Park Cancer Institute
Phase 2 Terminated
NCT02485834 2025-01-20
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT01167725 2024-12-27
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT05546411 2024-12-17
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT03329248 2024-12-12
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03563157 2024-12-11
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03009058 2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2 Terminated
NCT03512756 2024-11-06
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer
Tyme, Inc
Phase 2/3 Terminated
NCT04937738 2024-11-06
PECORINO
Ukrainian Society of Clinical Oncology
Phase 2 Terminated
NCT04428333 2024-10-09
INDUCE-4
GlaxoSmithKline
Phase 3 Terminated
NCT01285557 2024-09-19
DIGEST
Taiho Oncology, Inc.
Phase 3 Terminated
NCT04747470 2024-09-03
Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Terminated
NCT03586869 2024-08-27
QUILT-3.080: NANT Pancreatic Cancer Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03387085 2024-08-09
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03387111 2024-08-05
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT05009953 2024-07-11
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 2 Terminated
NCT03136406 2024-06-11
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03300544 2024-05-23
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT03387098 2024-05-22
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT03500874 2024-01-22
Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM
Sun Yat-sen University
Phase 3 Terminated
NCT01897454 2023-12-05
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
Albert Einstein College of Medicine
Phase 2 Terminated
NCT01133990 2023-11-07
FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
Eisai Inc.
Phase 1/2 Terminated
NCT01307956 2023-10-26
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
University of Nebraska
Phase 2 Terminated
NCT01047007 2023-09-21
A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00601198 2023-08-01
A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer
University of Cincinnati
Phase 2 Terminated
NCT00303628 2023-07-06
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
Eastern Cooperative Oncology Group
Phase 3 Terminated